The relationship of body mass index on patient reported outcomes after platelet-rich plasma versus microfragmented adipose tissue for knee osteoarthritis: A secondary analysis of a randomized controlled trial.

OBJECTIVE:Body mass index (BMI) is known to contribute to outcomes for patients with knee OA. Furthermore, BMI influences the protein expression of orthobiologic treatments like platelet-rich plasma (PRP) and microfragmented adipose tissue (MFAT). We performed a secondary analysis of the association of BMI with PROs for patients with knee OA who received either PRP or MFAT injections. METHODS:Seventy-one patients with knee OA were randomized to receive a single ultrasound-guided injection of PRP or MFAT. PRP was created from 180cc of anti-coagulated blood and processed using a double-spin, buffy-coat concentration system. MFAT was created using autologous lipoaspirate that was processed according to minimal manipulation guidelines. PROs, and osteoarthritis outcome scores (KOOS) were tracked for 12-months. RESULTS:Forty-nine patients (PRP=23, MFAT=26) completed 12-month follow-up. KOOS- Quality of life and activity of daily living subscores were inversely correlated (both p < 0.05) with BMI in the MFAT but not PRPgroup. KOOS-Pain and Sport subscores showed a trend towards inverse correlation with BMI in the MFAT group (p = 0.07 and p = 0.06, respectively), but not PRP.Conclusion: BMI was negatively associated with PROs in patients who received MFAT injections for knee OA, but not for patients receiving PRP.